Savara (YB4P) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Molgramostim | Autoimmune Pulmonary Alveolar Proteinosis | Phase III | Recruiting | Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP). | May 22, 2024 | ― |
| Molgramostim, Molgramostim Open-Label | Autoimmune Pulmonary Alveolar Proteinosis | Phase III | Active Not Recruiting | Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | Sep 03, 2020 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Molgramostim | Phase III | Autoimmune Pulmonary Alveolar Proteinosis | Recruiting | Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP). | May 22, 2024 | ― |
| Molgramostim, Molgramostim Open-Label | Phase III | Autoimmune Pulmonary Alveolar Proteinosis | Active Not Recruiting | Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | Sep 03, 2020 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Savara (DE:YB4P) have in its pipeline
Savara DE:YB4P is currently developing the following drugs: Molgramostim, Molgramostim, Molgramostim Open-Label. These drug candidates are in various stages of clinical development as the company works toward FDA approval.